{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of CI was not estimable because of low number of participants with events.","groupId":"OG000","lowerLimit":"20.0","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of CI was not estimable because of low number of participants with events.","groupId":"OG001","lowerLimit":"10.8","upperLimit":"NA","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"description":"Time to SSE was defined as the time duration (in months) between the date of randomization and the date of occurrence of the first SSE. Analysis was performed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Cabazitaxel 25 mg/m\\^2 IV infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic G-CSF as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).","id":"OG000","title":"Cabazitaxel"},{"description":"Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).","id":"OG001","title":"Abiraterone Acetate or Enzalutamide"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on ITT population.","reportingStatus":"POSTED","timeFrame":"From date of randomization until first SSE, or data cut-off whichever comes first (maximum duration: up to 141 weeks)","title":"Time to Symptomatic Skeletal Event","type":"SECONDARY","unitOfMeasure":"months"}